- Brentuximab vedotin treatment in clinical practice2018 | Third Faculty of Medicine
- Brentuximab vedotin in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma patients2013 | Faculty of Medicine in Hradec Králové
- Current treatment approaches in patients with newly diagnosed peripheral T-cell lymphoma and novel therapies-focusing on brentuximab vedotin2020 | Faculty of Medicine in Hradec Králové
- Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma patients in the Czech Republic2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Brentuximab vedotin in the treatment of lymphomas - practical experience2015 | Third Faculty of Medicine
- Brentuximab vedotin in the treatment of relapsed CD30 positive cutaneous lymphoma - results of an international, open label, randomised, phase 3, multicentre trial - ALCANZA2018 | Faculty of Medicine in Hradec Králové
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. SGN35-010Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: SGN35-014Publication without faculty affiliation
- Research Report University Hospital for clinical assessment SGN35-014Publication without faculty affiliation
- Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group2016 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Treatment of Refractory Systemic Hodgkin Lymphoma and Secondary CNS Involvement with Brentuximab Vedoti2021 | Third Faculty of Medicine
- Treatment and Prognosis of Relapsed or Refractory Hodgkin Lymphoma Patients Ineligible for Stem Cell Transplantation2014 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Komentář ke studii: Brentuximab vedotin v léčbě relabujícího/refrakterního Hodgkinova lymfomu - metaanalýza2015 | Third Faculty of Medicine
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial2019 | Faculty of Medicine in Hradec Králové
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma2022 | Faculty of Medicine in Hradec Králové
- Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy2018 | First Faculty of Medicine
- Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Léčba relapsu Hodgkinova lymfomu po autologní transplantaci monoterapií brentuximab vedotinem2017 | Third Faculty of Medicine
- Advanced stages of classical Hodgkin lymphoma - first-line treatment options2021 | Third Faculty of Medicine
- Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement2020 | Third Faculty of Medicine, Second Faculty of Medicine
- Current treatment approaches in patients with advanced-stage Hodgkin lymphoma2014 | Third Faculty of Medicine
- Hodgkin's Lymhoma - the Treatment Aproaches Development and Current Trends2015 | First Faculty of Medicine
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial2016 | First Faculty of Medicine
- Hodgkin lymphoma - hendless story Hodgkin lymphoma - endless story2019 | Third Faculty of Medicine
- Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era2023 | Faculty of Medicine in Hradec Králové
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma2018 | First Faculty of Medicine
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study2019 | First Faculty of Medicine
- Nivolumab v léčbě Hodgkinova lymfomu2017 | Third Faculty of Medicine
- Nivolumab v léčbě klasického Hodgkinova lymfomu2018 | Third Faculty of Medicine